In addition, HCC patients with higher FTL expression showed lower IC50 values of targeted drugs such as sorafenib, dasatinib, imatinib, roscovitine, sunitinib, thapsigargin, tipifarnib, temsirolimus, and rapamycin (p < 0.05) (Figure 6D–L). Here, FTL is linked to hepatocellular carcinoma.